Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 199c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of $1.30, $1.99 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $294.12 million versus the consensus estimate of $39.51 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Carvana (CVNA) PT Lowered to $85 at RBC Capital
• Sharon AI secures six-year compute deal with NVIDIA for Australia deployment